Kurt J. Hilzinger, a director at Outlook Therapeutics (NASDAQ:OTLK), purchased 400,000 shares of common stock on May 26, 2026.
The shares were bought at $0.4413 each, totaling $176,520. Following the purchase, Hilzinger directly owns 423,655 shares.
The insider buy comes as the stock has surged 46.59% over the past week, currently trading at $0.52.
In other news, Outlook Therapeutics plans to resubmit its Biologics License Application in June 2026 after the FDA confirmed efficacy for LYTENAVA. Meanwhile, BTIG downgraded the stock to Neutral from Buy. The company also raised $5 million in a registered direct offering.
